Evidence map›Paper›PMID 38517409›Full record

SynthesisCancer reports (Hoboken, N.J.)2024

Role of long non-coding RNAs in cholangiocarcinoma: A systematic review and meta-analysis.

Parnian Shobeiri, Razman Arabzadeh Bahri, Mohamad Mehdi Khadembashiri, Mohamad Amin Khadembashiri, Saba Maleki, Mohammad Eslami, Marzie Khalili Dehkordi, Amir Hossein Behnoush, Nima Rezaei

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Cancer reports (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Parnian ShobeiriSchool of medicine, Tehran University of Medical Sciences, Tehran, Iran.
Razman Arabzadeh BahriSchool of medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mohamad Mehdi KhadembashiriNeuromusculoskeletal Research Center, Iran University of Medical Sciences, Tehran, Iran.
Mohamad Amin KhadembashiriNeuromusculoskeletal Research Center, Iran University of Medical Sciences, Tehran, Iran.
Saba MalekiSchool of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Mohammad EslamiStudent Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.
Marzie Khalili DehkordiSchool of medicine, Tehran University of Medical Sciences, Tehran, Iran.
Amir Hossein BehnoushSchool of medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-9955-4227
Nima RezaeiNetwork of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.ORCID 0000-0002-3836-1827
Education and Research Network · INTehran University of Medical Sciences · IRIran University of Medical Sciences · IRGuilan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCholangiocarcinoma (CCA), as a rare malignancy of the biliary tree, has a poor prognosis most of the time. CCA is highly epigenetically regulated and several long non-coding RNAs (lncRNA) have been investigated to have a diagnostic and prognostic role in CCA. The current study aimed to assess the studies finding relevant lncRNAs in CCA systematically.

methodsInternational databases, including PubMed, Cochrane Library, and Embase, were comprehensively searched in order to identify studies investigating any lncRNA in CCA. After screening by title/abstract and full-text, necessary data were extracted. Random-effect meta-analysis was performed for pooling the areas under the curve (AUCs), specificity, and sensitivity of lncRNAs for the diagnosis of CCA.

resultsA total of 33 studies were chosen to be included in the final analysis, comprised of 2677 patients. Meta-analysis of AUCs for evaluation of CCA resulted in pooled AUC of 0.79 (95% CI: 0.75-0.82; I

conclusionBased on our findings, lncRNAs showed promising results as biomarkers in the diagnosis of CCA since they had acceptable sensitivity and specificity, in addition to the fact that improved survival in this poor prognosis cancer. Further studies might be needed to address this issue and find the best clinically useful lncRNA.

Indexed as

Bile Duct NeoplasmsBiomarkers, TumorCholangiocarcinomaRNA, Long NoncodingGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, TumorRNA, Long NoncodingCholangiocarcinomadiagnosislong non‐coding RNAmeta‐analysissystematic review

Identifiers

PMID38517409
PMCPMC10959185
OpenAlexW4393068620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.